Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyasu Yamashiro

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 19, 2015
[A case of Paclitaxel-induced peripheral neuropathy successfully treated with duloxetine]Satoshi Nagashima, Takayoshi Kiba, Yoshikazu Ogawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 18, 2008
[A case of primary breast cancer who responded remarkably to the neoadjuvant chemotherapy with the combination of docetaxel and cyclophosphamide]Hiroshi Yoshibayashi, Hiroshi Ishiguro, Masahiro Takada, et al.
Breast Cancer (Tokyo, Japan)|September 3, 2022
Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studiesYutaka Yamamoto, Hiroyasu Yamashiro, Andreas Schneeweiss, et al.
Annals of Surgical Oncology|August 16, 2015
Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast CancerTomoharu Sugie, Takayuki Kinoshita, Norikazu Masuda, et al.
Scientific Reports|December 27, 2022
Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancerMasahiro Takada, Michio Yoshimura, Takeshi Kotake, et al.
Breast (Edinburgh, Scotland)|July 15, 2019
Effectiveness and safety of surgical glove compression therapy as a prophylactic method against nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathyShigeru Tsuyuki, Kazuhiko Yamagami, Hiroshi Yoshibayashi, et al.
Breast Cancer (Tokyo, Japan)|February 16, 2020
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01Hiroyasu Yamashiro, Hiroji Iwata, Norikazu Masuda, et al.
Breast Cancer (Tokyo, Japan)|July 28, 2020
Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) studyYutaka Yamamoto, Hiroyasu Yamashiro, Uhi Toh, et al.
Breast Cancer : Basic and Clinical Research|July 18, 2018
Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational StudyHiroyasu Yamashiro, Masataka Sawaki, Norikazu Masuda, et al.
Breast Cancer (Tokyo, Japan)|April 23, 2022
Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC studyYuichiro Kikawa, Takeshi Kotake, Shigeru Tsuyuki, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Gan to Kagaku Ryoho. Cancer & Chemotherapy|May 19, 2015
[A case of Paclitaxel-induced peripheral neuropathy successfully treated with duloxetine]Satoshi Nagashima, Takayoshi Kiba, Yoshikazu Ogawa, et al.
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 18, 2008
[A case of primary breast cancer who responded remarkably to the neoadjuvant chemotherapy with the combination of docetaxel and cyclophosphamide]Hiroshi Yoshibayashi, Hiroshi Ishiguro, Masahiro Takada, et al.
Breast Cancer (Tokyo, Japan)|September 3, 2022
Factors affecting prognosis in patients treated with bevacizumab plus paclitaxel as first-line chemotherapy for HER2-negative metastatic breast cancer: an international pooled analysis of individual patient data from four prospective observational studiesYutaka Yamamoto, Hiroyasu Yamashiro, Andreas Schneeweiss, et al.
Annals of Surgical Oncology|August 16, 2015
Evaluation of the Clinical Utility of the ICG Fluorescence Method Compared with the Radioisotope Method for Sentinel Lymph Node Biopsy in Breast CancerTomoharu Sugie, Takayuki Kinoshita, Norikazu Masuda, et al.
Scientific Reports|December 27, 2022
Phase Ib/II study of nivolumab combined with palliative radiation therapy for bone metastasis in patients with HER2-negative metastatic breast cancerMasahiro Takada, Michio Yoshimura, Takeshi Kotake, et al.
Breast (Edinburgh, Scotland)|July 15, 2019
Effectiveness and safety of surgical glove compression therapy as a prophylactic method against nanoparticle albumin-bound-paclitaxel-induced peripheral neuropathyShigeru Tsuyuki, Kazuhiko Yamagami, Hiroshi Yoshibayashi, et al.
Breast Cancer (Tokyo, Japan)|February 16, 2020
Outcomes of trastuzumab therapy in HER2-positive early breast cancer patients: extended follow-up of JBCRG-cohort study 01Hiroyasu Yamashiro, Hiroji Iwata, Norikazu Masuda, et al.
Breast Cancer (Tokyo, Japan)|July 28, 2020
Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) studyYutaka Yamamoto, Hiroyasu Yamashiro, Uhi Toh, et al.
Breast Cancer : Basic and Clinical Research|July 18, 2018
Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational StudyHiroyasu Yamashiro, Masataka Sawaki, Norikazu Masuda, et al.
Breast Cancer (Tokyo, Japan)|April 23, 2022
Effectiveness of eribulin as first-line or second-line chemotherapy for HER2-negative hormone-resistant advanced or metastatic breast cancer: findings from the multi-institutional, prospective, observational KBCRN A001: E-SPEC studyYuichiro Kikawa, Takeshi Kotake, Shigeru Tsuyuki, et al.
Pageof 5